

Ifw

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF FIRST-CLASS MAILING

Attorney Docket No. : 202.2D2

Applicant(s) : Clarence N. Ahlem, et al


For : Pharmaceutical Compositions and Treatment Methods

Application serial No.: 10/602,330

Attorney : Daryl D. Muenchau, Registration No. 36,616

Date of Deposit : May 24, 2005

I hereby certify that the accompanying Transmittal, Information Disclosure Statement, 28 references, and return postage prepaid postcard are being deposited with the United States Postal Service First-Class Mail Post Office to Addressee service, pursuant to 37 CFR § 1.8, on the date indicated above and are addressed to the U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, Mail Stop Amendment.



Brenda Mannon-Freeman



PATENT
Docket No. 202.2D2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Clarence N. Ahlem, et al.
Application No. : 10/602,330
Filed : June 23, 2003
Title : Pharmaceutical Compositions and Treatment Methods
Examiner : Barbara P. Badio

Group Art Unit : 1617
Customer No. : 26551
Confirmation No. : 9052

INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed is form PTO-1449 listing 28 references that are also enclosed. No fee is required in accordance with 37 C.F.R. § 1.97(b).

Respectfully submitted,

HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated: May 24, 2005

By: Daryl D. Muenchau
Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall #400
San Diego, California, 92121
Telephone: (858) 587-9333
Customer No. 26,551

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.2D2	APPLICATION NO. 10/602,330
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(USE SEVERAL SHEETS IF NECESSARY)</p>		APPLICANT Clarence N. Ahlem, et al	
		FILING DATE June 23, 2003	GROUP 1617

U.S. PATENT DOCUMENTS

EXAMINER Approval Date	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

U.S. PATENT APPLICATION PUBLICATION DOCUMENTS

EXAMINER INITIAL	DOCUMENT SERIAL NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER Approval Date	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER Approval Date	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Araghi-Niknam et al., Modulation of immune dysfunction during murine leukaemia retrovirus infection of old mice by dehydroepiandrosterone sulphate (DHEAS), <i>Immunology</i> 90:344-349 (1997)
	Byron J, Nature of the erythropoietin-independent response of CFU-S to steroids, <i>Exp. Hematol.</i> 8:160-167 (1980)
	Byron J, Manipulation of the cell cycle of the hemopoietic stem cell, <i>Exp. Hemat.</i> 3:44-53 (1975)
	Crandall et al., Estrogens and hematopoiesis: characterization and studies on the mechanism of neutropenia, <i>J. Lab. Clin. Med.</i> 95(6):857-867 (1980)
	Evens et al., Androgens and erythropoiesis, <i>The J. of Clin. Pharmacology</i> pps. 94-101 (1974)
	Gianotti et al., Steroid therapy can modulate gut barrier function, host defense and survival in thermally injured mice, <i>J Surg Research</i> 62:53-58 (1996)
	Horn, Y., The effect of androgenic hormones on bone marrow of rats receiving chemotherapy, <i>Oncology</i> 25:512-519 (1971)
	Kang et al., Dehydroepiandrosterone and β -endorphin enhance IL-12 gene expression, <i>Taehan Misaengmulhak Hoechi (J. Korean Soc. Microbiology)</i> 31(4):399-404 (1996) (translation from Korean)
	Lardy et al., Ergosteroids II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone, <i>Steroids</i> 63:158-165 (1998)

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.2D2	APPLICATION NO. 10/602,330
	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE June 23, 2003	GROUP 1617

EXAMINER Approval Date	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Leroy et al., Estrogen-like effect of 5-androstene-3 β , 17 β -diol on the induction of fetal thymidine kinase in the rat uterus, <i>J. Steroid Biochem</i> 31(4):453-458 (1988)
	Loria et al., Mobilization of cutaneous immunity for systemic protection against infections, <i>Ann NY Acad Sci</i> 650:636-666 (1992)
	Loria et al., Regulation of the immune response by dehydroepiandrosterone and its metabolites, <i>J. Endocrinology</i> , 150:S209-S220 (1996)
	Manz et al., Methyl 17 β -Carboxyester Derivatives of Natural and Synthetic Glucocorticoids: Correlation Between Receptor Binding and Inhibition of in vitro Phytohaemagglutinin-Induced Lymphocyte Blastogenesis, <i>J. Clin. Chem. Clin. Biochem.</i> 21(2):69-75 (1983)
	Navarro et al., Androgen therapy for anemia in elderly uremic patients, <i>Int'l Urology and Nephrology</i> 32:549-557 (2001)
	Padgett et al., Endocrine regulation of murine macrophage function: effects of dehydroepiandrosterone, androstenediol, and androstenetriol, <i>J of Immunology</i> 84:61-68 (1998)
	Padgett et al., Endocrine regulation of the immune response to influenza virus infection with a metabolite of DHEA-androstenediol, <i>J. of Neuroimmunology</i> 78:203-211 (1997)
	Padgett et al., In vitro potentiation of lymphocyte activation by dehydroepiandrosterone, androstenediol and androstenetriol, <i>J. Immunol</i> 153(4):1544-1552 (1994)
	Padgett et al., Steroid hormone regulation of a polyclonal T _H 2 immune response, <i>Ann NY Acad Sci</i> 774:323-325 (1995)
	Pashko, L. et al., "Inhibition of DNA synthesis in mouse epidermis and breast epithelium by dehydroepiandrosterone and related steroids", <i>Carcinogenesis</i> , Vol. 2, No. 8, p. 717-721 (1981)
	Rosenblum et al., Androgenic hormones and human granulopoiesis in vitro, <i>Blood</i> 43:351-356 (1974)
	Sanchez-Medal, L., The hemopoietic action of androstanes, <i>Progress in Hematology</i> , pps. 111-136
	Sigg et al., 3 α -Acetoxyätiën-(8:9 oder 8:14)-säure-methylester, <i>Helvetica Chimica Acta</i> , 39(6):1507-1525 (1956) (translation from German)
	Steinzherz et al., Effect of lithium carbonate plus oxymetholone vs. lithium alone on chemotherapy-induced myelosuppression, <i>The American J of Pediatric Hematology/Oncology</i> 5(1):39-44 (1983)
	Weisz et al., Selective reactions of some steroids with diethyl dicarbonate, <i>Archiv der Pharmazie</i> 319:952-953 (1986)
	Whitnall et al., Androstenediol stimulates myelopoiesis but not lymphopoiesis in irradiated mice, <i>Blood</i> 90(10)(1), 175a (1997)
	Whitnall et al., Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice, <i>Int'l J of Immunopharmacology</i> 22:1-14 (2000)
	Whitnall et al., In Vivo radioprotection by 5-androstenediol: Stimulation of the immune system, <i>Radiation Research</i> 156:283-293 (2001)
	Yang et al., Inhibition of HIV-1 Latency Reactivation by Dehydroepiandrosterone (DHEA) and an Analog of DHEA, <i>Aids Research and Human Retroviruses</i> 9(8):747-754 (1993)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	